Clinical trials are moving faster, but speed alone isn’t enough. Stronger oversight, better integration, smarter technology, and closer collaboration all play a role in keeping execution on track. Here’s what modern trial operations require: https://t.co/mSH5Y9ZzJD
What if the key to improving immunotherapy is helping the immune system better “see” cancer? New research explores how changing the antigens tumors display could help turn “cold” tumors “hot” and open new treatment possibilities. https://t.co/FSiHyu2nOY
Women's health research is entering a chapter beyond reproductive health. A broader, lifecycle-based view is opening the door to new areas of innovation like FSIAD, PMDD, & digital health.
Here are 6 trends to watch: Shifting Priorities in Women’s Health: https://t.co/G2ZFoBI3iO
Advancing women’s health doesn’t happen in silos. We’ll be at the Women’s Health Innovation Summit, where collaboration across disciplines is helping shape the future of women’s health development.
See you there: https://t.co/JnywTdUmI5
#PremierResearch#WHIS
With highly perceptible treatment effects and structured therapeutic settings, sponsors need to think differently about how they generate and interpret evidence for #psychedelic therapies.
Our blog explores what it takes to build credible, durable data: https://t.co/8FyJy7mQ1E
At #MeetingOnTheMesa, Premier leaders across medical affairs, clinical development, and regulatory affairs will join discussions on advancing complex therapies.
Meet the team: https://t.co/bwyIgNaT4A
#AcceleratedApproval is not a shortcut around FDA’s standards for safety and efficacy. It’s a different path for establishing them, with confirmatory evidence still required.
Watch our recent webinar to learn more about how the pathway works: https://t.co/cdGmYJ5fZq
What’s next in oncology? Our team will be in Madrid for #ESMO26, where new data, treatment advances, and emerging science will offer a look at what’s ahead for cancer research and care. https://t.co/NrG9fuXjXq
#PremierResearch#Oncology
Timing is one of the most consequential decisions in marketing application readiness. Our new eBook explores how teams can identify key gaps, prioritize risk, and build a more controlled path to filing: https://t.co/a2P8Sf5LkL
#PremierResearch#RegulatoryAffairs
Adaptive trial designs are changing how sponsors approach early-phase #oncology studies, helping identify efficacy signals sooner and make smarter decisions.
Explore how precision medicine and adaptive designs are reshaping Phase 1 and 2 oncology trials.: https://t.co/0yBYXKUPiq
Dermatology development is raising the bar for efficacy, durability, safety, and meaningful patient outcomes. At #EADV2026, our team will be joining the conversations shaping what comes next.
Schedule a meeting with them: https://t.co/WPougWohHZ
#PremierResearch
Today’s standard of care may not be the standard an asset competes against at launch.
A strong #TargetProductProfile evolves with the evidence and the market, helping teams reassess the differentiation patients, physicians, and payers will value: https://t.co/olGkWHc2J7
From dose selection to study design, pharmacometrics is helping inform critical decisions across drug development. Our team will be at #ACoP2026, joining conversations around MIDD and the evolving role of quantitative science.
https://t.co/IL7G8qObO2
When billions are invested in bringing a drug to market, knowing when to keep going, slow down, or stop matters. Explore the key factors that can help guide development decisions: Development Programs: https://t.co/YMi8y3nFoR
#PremierResearch#CommercialStrategy
What a great evening in Seattle! Premier hosted a happy hour bringing together industry colleagues for great conversations and new connections. Thank you to everyone who joined us.
#PremierResearch
Regulatory expectations continue to evolve across global clinical development.
Nicole Stansbury will be at #ACRO2026, joining industry leaders for discussions on the issues shaping clinical research worldwide.
#PremierResearch#RegulatoryAffairs
Safe, quality care matters throughout a patient’s journey, especially for those with noncommunicable conditions requiring ongoing clinical care.
Gwyn Bebb shares why listening to patients, anticipating risks, and honoring their trust must remain central to scientific progress.
The Premier road show continues! Today, our team members are at CAR-TCR and Rare Trials Summit.
From advancing next-generation cell therapies to navigating the unique challenges of rare disease trials, there’s plenty to talk about.
#PremierResearch#RareDisease#CellTherapy
For Dr. Herrick, #BloodCancerAwarenessMonth is more than a moment to raise awareness. It’s personal.
She experienced firsthand how research, treatment, and dedicated physicians can change a life. We are proud to support research that brings hope to patients.
#PremierResearch